Lymphoblastic leukaemia and non-Hodgkin's lymphoma

British Medical Bulletin

Volumn 52, Issue 4, 1996, Pages 742-763

  Lilleyman, J S ^a   Pinkerton, C R ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; MELPHALAN; METHOTREXATE; PODOPHYLLOTOXIN; PREDNISONE; STEROID; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; HUMAN; IMMUNOPHENOTYPING; INTRATHECAL DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHATIC LEUKEMIA; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEX; TREATMENT OUTCOME;

EID: 0030444543     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011580     Document Type: Review

References (95)

1. Kinlen LJ. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer 1995; 71: 1-5
2. Robison LL, Ross JA. Epidemiology of leukaemias and lymphomas in childhood. Baillières Clin Paediatr 1995; 3: 639-57
3. Court-Brown WM, Doll R. Leukaemia in childhood and young adult life. BMJ 1961; 1: 981-8
4. Greaves MF, Colman SM, Beard MEJ et al. Geographical distribution of acute lymphoblastic leukaemia subtypes: second report of the collaborative group study. Leukemia 1993; 7: 27-34
5. Bennett JM, Catovsky D, Daniel MT et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981; 47: 553-61
6. Lilleyman JS, Hann IM, Stevens RF et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. Br J Haematol 1992; 81: 52-7
7. Ludwig W-D, Raghavachar A, Thiel E. Immunophenotypic classification of acute lymphoblastic leukaemia. Ballieres Clin Haematol 1994; 7: 235-62
8. Chen C-S, Sorensen PHB, Domer PH et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-93
9. Rivera GK. Advances in therapy for childhood non-B-lymphoblastic leukaemia. Baillière's Clin Haematol 1994; 7; 273-98
10. Pinkel D. Five-year follow up of 'total therapy' of childhood lymphocytic leukaemia. JAMA 1971; 216: 648-52
11. Berry OH, Pullen J, George S et al. Comparison of prednisone, vincristine, methotrexate and 6-mercaptopurine versus vincristine and prednisone induction therapy in childhood acute leukemia. Cancer 1975; 36: 98-102
12. Ortega JA, Nesbit ME, Donaldson MH et al. L-asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977; 37: 535-40
13. Chessells JM, Bailey CC, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council Trial UKALL X. Lancet 1994; 345: 143-8
14. Riehm H, Gadner H, Henze G et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hematol Blood Transfus 1990; 33: 439-50
15. Tubergen DG, Gilchrist GS, O'Brien RT et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. A Children's Cancer Group Phase III trial. J Clin Oncol 1993; 11: 527-37
16. Cammitta B, Mahoney D, Leventhal B et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher risk non-T, non-B acute lymphocytic leukaemia. A Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1383-9
17. Littman P, Coccia P, Bleyer WA et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Biol Physiol 1987; 13: 1443-9
18. Pullen J, Boyett J, Shuster J et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good risk and poor risk patients with B-progenitor acute lymphoblastic leukemia. A Pediatric Oncology Group study. J Clin Oncol 1993; 11: 839-49
19. Gale R, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 1315-8
20. Lilleyman JS. Importance of oral antimetabolite 'maintenance' therapy in childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1996; In press
21. Bleyer WA, Sather HN, Nickerson HJ et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Children's Cancer Study Group. J Clin Oncol 1991; 9: 1012-21
22. Lauer SJ, Pinkel D, Buchanan G et al. Cytosine arabinoside/cyclophosphamide pulses during continuing therapy for childhood acute lymphoblastic leukemia. Cancer 1987; 60: 2366-71
23. Sather H, Coccia P, Nesbit ME et al. Disappearance of the predictive value of prognostic variables in childhood acute lymphoblastic leukemia. Cancer 1981; 48: 370-6
24. Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995; 89: 364-72
25. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child 1991; 66: 462-6
26. Pui C-H. Childhood leukaemias. N Engl J Med 1995; 332: 1618-30
27. Pui C-H, Carrol AJ, Raimondi SC et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 1990; 75: 1170-7
28. Miller DR, Coccia PF, Bleyer WA et al. Early response to induction therapy as a predictor of disease free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1989; 7: 1087-95
29. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993; 83: 412-8
30. Cavé H, Guidal C, Rohrlich P et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994; 83: 1892-902
31. Butturini A, Rivera GK, Borlin MM, Gale RP. Which treatment for childhood acute lymphoblastic leukaemia in second remission? Lancet 1987; i: 429-32
32. Winwick NJ, Smith SD, Shuster J et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 271-8
33. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 1987; 56: 339-47
34. Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330-6
35. Pui C-H, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325 1682-7
36. Steinherz LJ, Steinherz PG, Tan CTC et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7
37. Schell MJ, Ochs JJ, Schriock EA, Carter M. A method for predicting adult height and obesity in long term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 128-33
38. Jenney MEM, Kissen GD. Late effects following treatment of childhood leukaemia and lymphoma. Ballière's Clin Paediatr 1995; 3: 715-33
39. Sklar C, Mertens A, Walter A et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr 1993; 123: 59-64
40. Wallace WHB, Shalet SM, Lendon M, Morris-Jones PH. Male fertility in long term survivors of acute lymphoblastic leukemia of childhood. Int J Androl 1991; 14: 312-9
41. Stansfeld AG, Diebold J, Noel H et al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292-3
42. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92
43. Rosenberg SA. Classification of lymphoid neoplasms. Blood 1994; 84: 1359-60
44. Hutchinson RE, Berard CW, Shuster JJ et al, B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol 1995; 13: 2023-32
45. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990; 1: 45-50
46. Slymen DJ, Miller TP, Lippman SM et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 986-93
47. Ribeiro PC, Pui CH, Murphy SB et al. Childhood malignant non-Hodgkin lymphomas of uncommon histology. Leukemia 1992; 6: 761-5
48. Haluska FG, Tsujimoto Y, Croce CM. The molecular genetics of non-Hodgkin's lymphomas. In: Magrath IT. ed. The Non-Hodgkin's Lymphoma. London: Edward Arnold, 1990
49. Shikano T, Arioka H, Kobayashi R et al. Acute lymphoblastic leukemia and non-Hodgkin's lymphoma with mediastinal mass. A study of 23 children; different disorders or different stages? Leukemia Lymphoma 1994; 13: 161-7
50. Bash RO, Hall S, Timmons CF et al. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group Study. Blood 1995; 86: 666-76
51. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-54
52. Stranks G, Height SE, Mitchell P et al. Deletions and rearrangements of CDKN2 in lymphoid malignancy. Blood 1995; 85: 893
53. Mason DY, Bastard C, Rimokh R et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q34. Br J Haematol 1990; 74: 161-8
54. Orscheschek K, Merz H, Hell J et al. Large-cell anaplastic lymphoma-specific translocation (t[2;5][p23;q35]) in Hodgkin's disease: indication of a common pathogenesis? Lancet 1995; 345: 87-90
55. Lorenzana AN, Reis M, Thorner P et al. Predictive biological and clinical markers related to outcome in anaplastic large cell lymphoma (Ki-1+) with the t(2;5) and other 2p23 abnormalities. Blood 1995; 86: 531a
56. Shepherd SF, A'Hern RP, Pinkerton CR. Childhood T-cell lymphoblastic lymphoma - does early resolution of mediastinal mass predict for final outcome? Br J Cancer 1995; 72: 752-6
57. Philip T, Pinkerton R, Biron P et al. Effective multiagent chemotherapy in children with advanced B-cell lymphoma: who remains the high risk patient? Br J Haematol 1987; 65: 159-64
58. Sandlund JT, Crist WM, Abromowitch M et al. Pleural effusion is associated with a poor treatment outcome in stage III small non-cleaved cell lymphoma. Leukemia 1991; 5: 71-4
59. Philip T, Hartmann O, Biron P et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118-24
60. Anderson JR, Jenkin RD, Wilson JF et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993; 11: 1024-32
61. Meadows AT, Sposto R, Jenkin RDT et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7: 92-9
62. Hvizdala EV, Berard C, Callihan T et al. Nonlymphoblastic lymphoma in children - histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 1189-95
63. Tubergen DG, Krailo MD, Meadows AT et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Children's Cancer Group study. J Clin Oncol 1995; 13: 1368-76
64. Patte C, Kalifa C, Flamant F et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992; 20: 105-13
65. Wheeler K, Chessells JM. UKALL X - an effective treatment for stage III mediastinal non-Hodgkin's lymphoma. Arch Dis Child 1990; 65: 252-4
66. Eden OB, Hann I, Imeson J et al. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 1992; 82: 310-6
67. Reiter A, Schrappe M, Parwaresch R et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-72
68. Patte C, Philip T, Rodary C et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123-32
69. Hann IM, Eden OB, Barnes J, Pinkerton CR. 'MACHO' chemotherapy for stage IV B cell lymphoma and B cell acute lymphoblastic leukaemia of childhood. Br J Haematol 1990; 76: 359-64
70. Murphy SB, Bowman WP, Abromowitch M et al. Results of treatment of advanced stage Burkitt's lymphoma and B cell (Sig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 1732-9
71. Sandlund JT, Santana V, Abromowitch M et al. Large cell non-Hodgkin lymphoma of childhood: clinical characteristics and outcome. Leukemia 1994; 8: 30-4
72. Gordon BG, Weisenburger DD, Warkentin PI et al. Peripheral T-cell lymphoma in childhood and adolescence. A clinicopathologic study of 22 patients. Cancer 1993; 71: 257-63
73. Bucsky P, Favara B, Feller AC et al. Malignant histocytosis and large cell anaplastic (Ki-1) lymphomas in childhood: guidelines for differential diagnosis - Report of the Histiocyte Society. Med Pediatr Oncol 1994; 22: 200-3
74. Saha V, Eden OB, Hann I et al. Primary extra-thoracic T-cell non-Hodgkin's lymphoma of childhood. The United Kingdom Children's Cancer Study Group. Leukemia 1995; 9: 40-3
75. Paulli M, Berti E, Rosso R et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin - clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization of Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343-54
76. Chakravarti V, Kamani NR, Bayever E et al. Bone marrow transplantation for childhood Ki-lymphoma. J Clin Oncol 1990; 8: 657-60
77. Sandlund JT, Pui CH, Roberts WM et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the (t2;5)(p233;q35). Blood 1994; 84: 2467-71
78. + large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 895-8
79. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumour necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995 85: 1-14
80. Gasparini M, Gianni C, Morandi F et al. Large-cell anaplastic Ki-1+ lymphoma of children. Med Pediatr Oncol 1988; 16: 406
81. Reiter A, Schrappe M, Tiemann M et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899-908
82. Brugieres L, Caillaud JM, Patte C et al. Malignant histiocytosis: therapeutic results in 127 children treated with a single polychemotherapy regimen. Med Pediatr Oncol 1989; 17: 193-6
83. Egeler RM, Schmitz L, Sonneveld P et al. Malignant histiocytosis: a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. Med Pediatr Oncol 1995; 25: 1-7
84. Gordon BG, Dennis D, Weisenburger WG et al, Peripheral T-cell lymphoma in children and adolescents: role of bone marrow transplantation. Leukemia Lymphoma 1994 14: 1-10
85. Cheng AL, Su I-J, Chen CC et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol 1994; 12: 1185-92
86. Lin K-H, Su I-J, Chen RL, et al. Peripheral T-cell lymphoma in childhood: a report of five cases in Taiwan. Med Pediatr Oncol 1994; 23: 26-35
87. Todeschini G, Ambrosetti A, Meneghini V et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804-8
88. Lazzarino M, Orlandi E, Paulli M et al. Primary mediastinal B-cell lymphoma with sclerosis an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306-13
89. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-8
90. Fischer A, Blanche S, Le Bidois J et al, Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-6
91. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 45: 9-13
92. Czuczman MS, Straus DJ, Divgi CR et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2021-9
93. Dyer MJS, Hale G, Marcus R et al. Remission induction in patients with lymphoid malignancies using unconjugated Campath-1 monoclonal antibodies. Leukemia Lymphoma 1990; 2: 179-93
94. McManaway ME, Neckers LM, Loke SL et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808-10
95. Shurtleff S, Buijs A, Behm F, Rubnitz J et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-9